Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Inclusion Criteria: * Prior diagnosis of NB or ganglioneuroblastoma either by histologic verification and/or demonstration of tumor cells in the bone marrow with increased catecholamine levels. * Male or female subjects ≤ 26 years of age * Diagnosis of high risk NB at initial diagnosis or if non-high risk at time of initial diagnosis must have had evidence of metastatic progression when \> 18 months of age. * Measurable or evaluable disease * Lansky or Karnofsky performance status score of ≥ 50 * Life expectancy of ≥ 8 weeks. * Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment onto this study. * ≥ 7 days since last chemotherapy or biologic therapy administration * No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollment. Topical Administration (e.g. inhaled or dermatologic) is allowed. * ≥ 3 half-lives or 30 days from time of last dose of anti-tumor directed antibody therapy, whichever is shorter from time of enrollment * ≥ 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion). Patients who received stem cell infusion following non-myelo-ablative therapy are eligible once they meet all other eligibility requirements. Patient must NOT have received a prior allogeneic hematopoietic stem cell transplant. * No prior genetically modified cell therapy that is still detectable. * Must not be receiving external beam radiat…